ArticleLeukemia2019
Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis.
Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis.Blood neoplasia · 2025Trial
- Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.Annals of hematology · 2023Trial
- Trial
- Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Trial
- Daratumumab monotherapy for relapsed AL amyloidosis: a single center retrospective analysis.Blood research · 2026Article
- Diagnostic and Therapeutic Aspects of Monoclonal Gammopathies of Renal Significance (MGRS): An Update.Diagnostics (Basel, Switzerland) · 2024Review
- Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis.Therapeutics and clinical risk management · 2023Review
- Targeted treatments of AL and ATTR amyloidosis.Heart failure reviews · 2022Review
- Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis.Cancer cell international · 2022Review
- Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.American journal of hematology · 2022Article
- Immunotherapy in AL Amyloidosis.Current treatment options in oncology · 2022Review
- Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.Blood cancer journal · 2022Article
- Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network).Journal of personalized medicine · 2022Article
- Kidney injury and disease in patients with haematological malignancies.Nature reviews. Nephrology · 2021Review
- Comprehensive Review of AL amyloidosis: some practical recommendations.Blood cancer journal · 2021Review
- Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.Blood cancer journal · 2021Review
- Review
- Characterization and prognostic implication of delayed complete response in AL amyloidosis.European journal of haematology · 2021Article
- Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.Blood cancer journal · 2021Article
- Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.Blood cancer journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30267007What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.